Developments in liposomal drug delivery systems

Развитие липосомальных систем доставки лекарственных средств
Pieter R. Cullis, Norbert Maurer, David B. Fenske
2001-11-01

antisense oligonucleotidesgene therapyliposomal drug delivery systemslong-circulating liposomessystemic drug administration
Liposomes are the leading drug delivery systems for the systemic (iv.) administration of drugs. There are now liposomal formulations of conventional drugs that have received clinical approval and many others in clinical trials that bring benefits of reduced toxicity and enhanced efficacy for the treatment of cancer and other life-threatening diseases. The mechanisms giving rise to the therapeutic advantages of liposomes, such as the ability of long-circulating liposomes to preferentially accumulate at disease sites including tumours, sites of infection and sites of inflammation are increasingly well understood. Further, liposome-based formulations of genetic drugs such as antisense oligonucleotides and plasmids for gene therapy that have clear potential for systemic utility are increasingly available. This paper reviews the liposomal drug delivery field, summarises the success of liposomes for the delivery of small molecules and indicates how this success is being built on to design effective carriers for genetic drugs.
1
Liposomal delivery of genetic drugs, including antisense oligonucleotides and plasmids for gene therapy, is increasingly available and shows potential for systemic treatment.
2
Liposomal formulations of conventional drugs have achieved clinical approval and reduced toxicity while enhancing efficacy in cancer and other life-threatening diseases.
3
Long-circulating liposomes can preferentially accumulate at tumours, infection sites, and inflammation sites, underpinning their therapeutic advantages.
4
Many additional liposomal drug formulations remain in clinical trials, indicating continued development beyond currently approved products.
5
The field is extending the demonstrated success of liposomes with small-molecule drugs to develop effective carriers for genetic therapeutics.

liposomal drug delivery systems and formulations for systemic administration of conventional and genetic drugs

therapeutic efficacy, reduced toxicity, disease-site accumulation, and design of liposomal carriers for small-molecule and genetic drugs

Publication Details
Publication Date
2001-11-01
Journal
Publisher
ISSN
Cited by
344
Access Type
Author Information
Authors
Pieter R. Cullis
Norbert Maurer
David B. Fenske
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%